Use of low-dose sulodexide in IgA nephropathy patients on renin-angiotensin system blockades
Kidney Research and Clinical Practice
;
: 163-169, 2012.
Article
in English
| WPRIM
| ID: wpr-205940
ABSTRACT
BACKGROUND:
Despite using renin-angiotensin system (RAS) blockades, some of the patients with immunoglobulin A (IgA) nephropathy often had persistent proteinuria of more than 500mg/d. They need to be managed further by alternative methods to halt the progression of the disease; these methods could also be applied safely over a long period of time. In this context, sulodexide has been studied for the management of diabetic nephropathy.METHODS:
A retrospective review was carried out involving 20 patients with IgA nephropathy who had been taking sulodexide (50mg daily) as an add-on therapy together with an optimal dose of RAS blockades during 2008-2009. We evaluated the proteinuria reduction rates and renal function changes.RESULTS:
During 11.1+/-72.7 months of follow-up duration, urinary protein-to-creatinine ratio (UPCR) decreased for 1.57+/-0.6 to 1.17+/-0.7 g/g (P=0.032). Twenty-five percent of the patients showed a greater than 50% reduction of UPCR, and 40% had a UPCR of less than 1.0g/g at their final observations. The analysis of the factors contributing to the effect found that a higher pretreatment UPCR showed a significant correlation with the UPCR decrease (r=0.45, P=0.047). Neither the adverse effects nor the renal function impairments were documented during the management.CONCLUSION:
Low-dose sulodexide has an additional modest antiproteinuric effect on IgA nephropathy undergoing RAS blockade therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Proteinuria
/
Renin-Angiotensin System
/
Immunoglobulin A
/
Retrospective Studies
/
Follow-Up Studies
/
Glomerulonephritis, IGA
/
Glycosaminoglycans
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Kidney Research and Clinical Practice
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS